Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2019; 08(02): 098-101
DOI: 10.4103/sajc.sajc_203_17
ORIGINAL ARTICLE: GI Cancers

Efficacy of preoperative chemoradiotherapy in downstaging rectal cancer and its impact on the long-term outcome

Janaki Gururajachar Manur
Department of Radiotherapy, M. S. Ramaiah Medical College, Bengaluru, Karnataka
,
Rahil Bharatbhai Patel
Department of Radiotherapy, M. S. Ramaiah Medical College, Bengaluru, Karnataka
,
Sathish Chandramouli
Department of Surgical Oncology, M. S. Ramaiah Medical College, Bengaluru, Karnataka
› Author Affiliations Financial support and sponsorship: Nil.
› Further Information
  PDF Download Permissions and Reprints

Abstract

Introduction: Response to preoperative chemoradiation (PRTCT) for rectal cancer predicts the long-term outcome. Context: Tertiary care hospital. Aims: The aim is to study the factors affecting the response to chemoradiation. Settings and Design: Retrospective. Materials and Methods: Twenty-three patients of rectal cancer undergoing PRTCT followed by surgery and adjuvant chemotherapy were followed up for 20–56 months. Postoperative response, tumor downstaging and nodal downstaging were correlated with the disease status. Results: Tumor downstaging was seen in 11 (50%) and nodal downstaging in 12 (63.15%) patients. Nodal downstaging was statistically significant with P = 0.004. Pathological complete response (PCR) was seen in one patient and partial response (PR) in 17 patients. Thirteen (72.2% of patients) were alive and disease free and the negative nodal status correlated with long-term control with P = 0.04. Conclusion: Most patients of rectal cancer show PR to PRTCT, and the benefit is more for node-positive patients. Nodal PCR is associated with a higher chance of long-term disease control.

Key words

Downstaging - long-term outcome - preoperative radiation - rectal cancer


Publication History

Article published online:
21 December 2020

© 2019. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Nooyi SC, Murthy NS, Shivananjaiah S, Sreekantaiah P, Mathew A. Trends in rectal cancer incidence – Indian scenario. Asian Pac J Cancer Prev 2011;12:2001-6.
  • 2 Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-40.
  • 3 Rohit M, Rakesh K, Thapesh B, Rajesh G, Kim V, Pragyat T, et al. Is neoadjuvantchemoradiation a gold standard for carcinoma rectum? A comprehensive analysis of outcomes and prognostic factors from a tertiary care centre from India. Int J Curr Res 2017;9:47616-9.
  • 4 Svenja T, Rupent L. Tumour regressive grading gastrointestinal carcinoma after neoadjuvant treatment. Front Oncol 2013;3:262.
  • 5 Engineer R, Basu T, Chopra S, Arya S, Patil P, Mehta S, et al. Factors influencing response to neoadjuvant chemoradiation and outcomes in rectal cancer patients: Tertiary Indian cancer hospital experience. J Gastrointest Oncol 2015;6:155-64.
  • 6 Yeo SG, Kim DY, Kim TH, Chang HJ, Oh JH, Park W, et al. Pathologic complete response of primary tumor following preoperative chemoradiotherapy for locally advanced rectal cancer: Long-term outcomes and prognostic significance of pathologic nodal status (KROG 09-01). Ann Surg 2010;252:998-1004.
  • 7 Dhadda AS, Zaitoun AM, Bessell EM. Regression of rectal cancer with radiotherapy with or without concurrent capecitabine – Optimising the timing of surgical resection. Clin Oncol (R Coll Radiol) 2009;21:23-31.
  • 8 Huntington CR, Boselli D, Symanowski J, Hill JS, Crimaldi A, Salo JC, et al. Optimal timing of surgical resection after radiation in locally advanced rectal adenocarcinoma: An analysis of the national cancer database. Ann Surg Oncol 2016;23:877-87.
  • 9 Sirohi B, Barreto SG, Patkar S, Gupta A, DeSouza A, Talole S, et al. Down-staging following neoadjuvant chemo-radiotherapy for locally advanced rectal cancer: Does timing of surgery really matter? Indian J Med Paediatr Oncol 2014;35:263-6.
  • 10 de Campos-Lobato LF, Geisler DP, da Luz Moreira A, Stocchi L, Dietz D, Kalady MF, et al. Neoadjuvant therapy for rectal cancer: The impact of longer interval between chemoradiation and surgery. J Gastrointest Surg 2011;15:444-50.
  • 11 Francois Y, Nemoz CJ, Baulieux J, Vignal J, Grandjean JP, Partensky C, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: The Lyon R90-01 randomized trial. J Clin Oncol 1999;17:2396.
  • 12 Maas M, Nelemans PJ, Valentini V, Das P, Rödel C, Kuo LJ, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: A pooled analysis of individual patient data. Lancet Oncol 2010;11:835-44.
  • 13 Ha YH, Jeong SY, Lim SB, Choi HS, Hong YS, Chang HJ, et al. Influence of preoperative chemoradiotherapy on the number of lymph nodes retrieved in rectal cancer. Ann Surg 2010;252:336-40.
  • 14 Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006;93:1215-23.